LIFERIVER(SH:688317) Ge Long Hui A P P·2026-01-22 07:51Core Viewpoint - Zhijiang Biotech (688317.SH) is expected to report a net loss attributable to shareholders of the parent company for the year 2025, with estimates ranging from -32 million to -47 million yuan, indicating a significant decline in profitability compared to the previous year [1] Financial Performance - The projected net loss represents an increase in losses of 80.46 million to 95.46 million yuan compared to the same period last year, reflecting a year-on-year reduction in loss margin of 63.13% to 74.89% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between -39 million and -58 million yuan, with a reduction in losses of 70.27 million to 89.27 million yuan compared to the previous year, indicating a year-on-year reduction in loss margin of 54.78% to 69.60% [1] Reasons for Performance - The primary reasons for the company's expected losses include a decline in sales of main products, the implementation of centralized procurement policies leading to price reductions, and an increase in the value-added tax rate on self-produced reagent products to 13%, which has negatively impacted revenue [1] - Additional factors contributing to the losses include a decrease in financial income and reduced foreign exchange gains [1] Strategic Response - The company is actively responding to market competition by enhancing product research and development, optimizing cost reduction and efficiency measures, and exploring potential opportunities to continuously improve product competitiveness and operational capabilities [1] - The narrowing of losses this year is attributed to a reduction in asset impairment losses and the effective implementation of cost control measures [1]